About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors

Citation:

European Cardiology Review 2017;12(1):30–2

Coronary Flow Velocity Reserve Assessment with Transthoracic Doppler Echocardiography

Citation:

European Cardiology Review 2015;10(1):12–8

Cholesteryl Ester Transfer Protein Inhibitors – Future Soon to be REVEALed

Citation:

European Cardiology Review 2015;10(1):64–7

At the Heart of Brain Disorders – Preventing Cognitive Decline and Dementia

Citation:

European Cardiology Review 2015;10(1):60–3